Clinical evolution of patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin

Authors

  • Iraida Caballero-Aguirrechu Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Yhanet Leonor Pomacussi-Villca Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Faustino Antonio Zabala-Rodríguez Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Nino López-Caballero Instituto de Ciencias Básicas y Preclínicas “Victoria de Girón”, La Habana, Cuba.
  • Daniel Carballo-Torres Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Leandro Calzada-Piquera Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Jorge Luis Hernández-Castro Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.
  • Claudia Roche-Albernas Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, La Habana, Cuba.

DOI:

https://doi.org/10.48193/revistamexicanadeurologa.v83i3.949

Keywords:

Calmette-Guérin bacillus, transurethral resection, intravesical therapy, relapse/progression

Abstract

Introduction: In non-muscle-invasive high-grade carcinoma of the bladder, after resection, intravesical treatment with bacillus Calmette-Guérin is recommended.

Objective: To characterize the patients with CVNMI treated with 40 mg of the bacillus, safety, and recurrence/progression rate pattern.

Methodology: A descriptive study of 77 patients from the Hospital Hermanos Ameijeiras, treated from 2012 to 2016. Cox logistic regression and Kaplan-Meier survival curves were used, with 0,05 significance level (95% confidence interval).

Results and value: The mean age was 70.2 years, 80.5% male and 85.7% smokers. High-grade lesions, bladder lateral site, and smaller than 3 cm predominated (70%). Rate to recurrence/progression of patients was 50.6/39.1 %. Progression-free survival was 4.7 years, significant in those with multiple, high-grade, and T1 lesions (p < 0.05). The main adverse events were cystitis and grade 1-2 fever.

Conclusions: male patients and smokers predominated, as well as smaller and high-grade tumors. The relationship of progression with the presence of high grade, female sex and old age was significant. BCG administration at 40 mg, up to 18 doses was safe and beneficial in overall survival, but not in relapse/progression-free survival, in relation to the presence of T1, multiple, and high-grade lesions.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49. doi: https://doi.org/10.3322/caac.21660

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020;8(1):15. doi: https://doi.org/10.3390/medsci8010015

Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54. https://doi.org/10.3322/caac.21440

Ministerio de Salud Pública. Anuario Estadístico de Salud 2020. Cuba: Ministerio de Salud Pública; 2020 p. 204. https://salud.msp.gob.cu/wp-content/Anuario/Anuario-2020

European Association of Urology. EAU Guidelines. Annual Congress Milan 2021. The Netherlands: European Association of Urology; 2021. doi: https://www.europeanurology.com

Mugiya S, Nagata M, Takayama T, Ozono S, Ito T, Maruyama S, et al. Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG. Hinyokika Kiyo. 2004 Jul;50(7):469-73. https://pubmed.ncbi.nlm.nih.gov/15334890/

Schmidt S, Kunath F, Coles B, Draeger DL, Krabbe L-M, Dersch R, et al. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2020;1(1):CD011935. doi: https://doi.org/10.1002/14651858.CD011935.pub2

Pramod SV, Safriadi F, Hernowo BS, Dwiyana RF, Batista B. Smoking history, smoking intensity, and type of cigarette as risk factors of bladder cancer: A literature review. Urological Science. 2020;31(4):147. doi: https://doi.org/10.4103/uros.uros_6_20

Mateu L, García-Cruz E, Asiaín I, Castañeda R, Carrión A, Huguet J, et al. Un mayor índice de comorbilidad de Charlson se relaciona con características más agresivas de los tumores vesicales de novo. Actas Urológicas Españolas. 2016;40(1):23–8. doi: https://doi.org/10.1016/j.acuro.2015.06.006

Rivera MA. Caracterización clínica, epidemiológica y anatomopatológica de los pacientes con cáncer de vejiga. Revista Cubana de Urología. 2018;7(0):45. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=87904

Liu Y, Lu J, Huang Y, Ma L. Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer. Journal of Oncology. 2019;2019:e6230409. doi:https://doi.org/10.1155/2019/6230409

Rodríguez AM, Vaillant S, Moya C, Acosta M, Fajardo J. Correspondencia ecográfica y tomográfica en el diagnóstico de cáncer de vejiga. MediSan. 2020;24(05):861–74. https://www.redalyc.org/articulo.oa?id=368464850008

Citarella D, Quiroga Matamoros W, Fernandez F, Patiño I, Estrada A. Guía de manejo en cáncer vesical. Urología Colombiana. 2016;25(2):154–68. doi: https://doi.org/10.1016/j.uroco.2016.03.001

Kamat AM, Gontero P, Palou J. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin? European Urology Oncology. 2020;3(2):252–7. doi: https://doi.org/10.1016/j.euo.2019.06.013

Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J. Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. JCO. 2015 Feb 20;33(6):643–50. doi: https://doi.org/10.1200/jco.2014.57.6967

Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology. 2017;72(5):801–13. https://doi.org/10.1016/j.eururo.2017.04.015

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. European Urology. 2016;69(1):60–9. doi: https://doi.org/10.1016/j.eururo.2015.06.045

Lenis AT, Lec PM, Chamie K, MSHS M. Bladder Cancer: A Review. JAMA. 2020;324(19):1980–91. doi: https://doi.org/10.1001/jama.2020.17598

Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, & Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. The Journal of urology, 2020; 164(3 Pt 1): 680–684. https://doi.org/10.1016/s0022-5347(05)67280-1

Sylvester RJ, Van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-477. https://doi:10.1016/j.eururo.2005.12.031

Del Giudice F, Busetto GM, Gross MS, et al. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. J Cancer Res Clin Oncol. 2021;147(10):3073-3080. https://doi:10.1007/s00432-021-03571

Downloads

Published

2023-08-17

Issue

Vol. 83 No. 3 (2023): May-June

Section

Original articles

License

Copyright (c) 2023 Revista Mexicana de Urología

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.